Literature DB >> 34322862

Quality of Health Economic Evaluations in Mainland China: A Comparison of Peer-Reviewed Articles in Chinese and in English.

Jiehua Cheng1, Yu Zhang1, Ailin Zhong1, Miao Tian2, Guanyang Zou1, Xiaping Chen3, Hongxing Yu3, Fujian Song4, Shangcheng Zhou5.   

Abstract

OBJECTIVE: Our objective was to assess the incidence and quality of reporting of published health economic evaluations in mainland China and compare the quality of peer-reviewed articles in Chinese and English.
METHODS: A comprehensive search was conducted for economic evaluations pertaining to China published from 2006 to 2015 using the PubMed, CBM, CMCC, CNKI, VIP, and Wanfang databases. All studies in English that met the inclusion criteria were included. For studies in Chinese, 200 sampled studies were included according to the random seeds method, and the same number of the most-cited studies in Chinese as those in English were included according to the number of citations and journal grades. Researchers independently assessed the quality of the studies using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.
RESULTS: After literature search and screening, a total of 310 studies were identified. The majority of these studies were cost-effectiveness studies (82.26%). Scores among different CHEERS items varied greatly. There was a gap between the average quality scores of the studies published in Chinese and those published in English (49.78 ± 9.31 vs. 82.48 ± 17.69) and between the average quality scores of the included most-cited studies in Chinese and English, which was slightly smaller (54.08 ± 10.27 vs. 82.48 ± 17.69). The methods, results, and discussion sections of studies published in Chinese were of low quality.
CONCLUSION: The quality of reporting of health economic evaluations in mainland China has developed slowly. Most of the included studies were incomplete in the presentation of content, making the results less reliable. It is important to standardize and improve the quality of Chinese health economic research.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Year:  2021        PMID: 34322862     DOI: 10.1007/s40258-021-00674-0

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  57 in total

Review 1.  The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal.

Authors:  Brennan M R Spiegel; Laura E Targownik; Fasiha Kanwal; Vincent Derosa; Gareth S Dulai; Ian M Gralnek; Chiun-Fang Chiou
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

2.  Transcatheter amplatzer occlusion and surgical closure of patent ductus arteriosus: comparison of effectiveness and costs in a low-income country.

Authors:  Zhaoyang Chen; Lianglong Chen; Liming Wu
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

3.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

4.  Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases.

Authors:  L Duan; M Huang; H Yan; Y Zhang; F Gu
Journal:  J Endocrinol Invest       Date:  2015-03-18       Impact factor: 4.256

5.  Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.

Authors:  Jing Deng; Shuyan Gu; Hui Shao; Hengjin Dong; Dajin Zou; Lizheng Shi
Journal:  J Med Econ       Date:  2015-08-20       Impact factor: 2.448

6.  Cost-effectiveness of a hypertension control intervention in three community health centers in China.

Authors:  Yamin Bai; Yanfang Zhao; Guijing Wang; Huicheng Wang; Kejun Liu; Wenhua Zhao
Journal:  J Prim Care Community Health       Date:  2013-01-07

7.  Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.

Authors:  Xin-Zu Chen; Kun Jiang; Jian-Kun Hu; Bo Zhang; Hong-Feng Gou; Kun Yang; Zhi-Xin Chen; Jia-Ping Chen
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

8.  Universal screening or prophylactic treatment for Chlamydia trachomatis infection among women seeking induced abortions: which strategy is more cost-effective?

Authors:  Shumin Chen; Jianhong Li; Anneke van den Hoek
Journal:  Sex Transm Dis       Date:  2007-04       Impact factor: 2.830

9.  Collecting and analysing cost data for complex public health trials: reflections on practice.

Authors:  Neha Batura; Anni-Maria Pulkki-Brännström; Priya Agrawal; Archana Bagra; Hassan Haghparast-Bidgoli; Fiammetta Bozzani; Tim Colbourn; Giulia Greco; Tanvir Hossain; Rajesh Sinha; Bidur Thapa; Jolene Skordis-Worrall
Journal:  Glob Health Action       Date:  2014-02-18       Impact factor: 2.640

10.  The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.

Authors:  Dongfeng Gu; Jiang He; Pamela G Coxson; Petra W Rasmussen; Chen Huang; Anusorn Thanataveerat; Keane Y Tzong; Juyang Xiong; Miao Wang; Dong Zhao; Lee Goldman; Andrew E Moran
Journal:  PLoS Med       Date:  2015-08-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.